Fresh AIMMs for elite responders
AIMM's elite responder platform points to modified protein antigens in cancer
AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications.
The company is one of a handful of players mining the immune systems of cancer patients successfully treated with immunotherapies for therapeutic antibodies, and the first to disclose the targets it has found.
AIMM launched in 2004 with a focus on infectious disease and spent 12 years developing mAbs for pharmas with funding from its founders, a 2009 €1 million ($1.4 million) angel investment from Life Sciences Fund Amsterdam, and revenues from licensing deals with partners including the MedImmune Inc. unit of AstraZeneca plc, the Genentech Inc. unit of Roche, the Crucell N.V. unit of Johnson & Johnson and Cosmo Pharmaceuticals N.V.
Its lead asset, an RSV mAb partnered with AstraZeneca, was identified in blood from a retired kindergarten teacher who never showed signs of RSV infection despite years of exposure to